In TNBC, Pathologic Complete Response May Vary by Race/Ethnicity
Among patients with triple-negative breast cancer (TNBC) who received neoadjuvant chemotherapy, the odds of achieving pathologic complete response (pCR) and improved overall survival (OS) may vary by race/ethnicity, according to results from a retrospective cohort study. Compared with white women, Black women with TNBC were less likely to achieve pCR (OR 0.89, 95% CI 0.83-0.95, […]
Clinical Challenges: Sequencing in Metastatic TNBC
As new treatment options continue to emerge for triple-negative breast cancer (TNBC), sequencing of therapy promises to get ever more complicated. TNBC had been estimated to account for about 15% of all breast cancer diagnoses, but that proportion shrank with the new HER2-low designation, which accounts for approximately one-third of patients diagnosed with TNBC. An […]
Targeted Combo Flops as First-Line Treatment in Advanced Breast Cancer
PARIS — A novel combination failed to improve the clinical benefit rate (CBR) in advanced triple-negative breast cancer (TNBC) compared with chemoimmunotherapy, a randomized trial showed. Adding the anti-CD73 antibody oleclumab to durvalumab (Imfinzi) and chemotherapy led to clinical benefit (response plus stable disease) in 43% of patients by 24 weeks as compared with 44% […]